Poly(ADP-ribose) polymerase-1/2 inhibitors (PARPi) are the first class of targeted therapies to show clinical benefit in prostate cancer and are used as standard therapy for genetically stratified metastatic and castrate-resistant prostate cancers (mCRPC) with BRCA-mutant (germline (gBRCA) or somatic (sBRCA)) or altered PALB2 status.6, 8ATM-mutant metastatic prostate cancer is currently being assessed for response to ataxia telangiectasia and rad3-related inhibitor therapies.9 Here, PARP1 is linked to prostate cancer.